Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.
about
Inducing Oncoprotein Degradation to Improve Targeted Cancer TherapyTargeting Hsp90 in urothelial carcinomaDual inhibition of EGFR at protein and activity level via combinatorial blocking of PI4KIIα as anti-tumor strategy.CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFRThe preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.High-throughput screening identifies aclacinomycin as a radiosensitizer of EGFR-mutant non-small cell lung cancerEmodin suppresses maintenance of stemness by augmenting proteosomal degradation of epidermal growth factor receptor/epidermal growth factor receptor variant III in glioma stem cells.The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.Patient-derived heavy chain antibody targets cell surface HSP90 on breast tumors.The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells.The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma modelHSP90 Inhibitors, Geldanamycin and Radicicol, Enhance Fisetin-Induced Cytotoxicity via Induction of Apoptosis in Human Colonic Cancer Cells.HSP90 Inhibitor SNX5422/2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype of Head and Neck Squamous Cell Carcinoma.Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization.Cancer subclonal genetic architecture as a key to personalized medicine.A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer.Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts.Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress.Chlamydia-infected cells shed Gp96 to prevent chlamydial re-infection.HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells.Graphene nanoribbons elicit cell specific uptake and delivery via activation of epidermal growth factor receptor enhanced by human papillomavirus E5 protein.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integrationUbiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma.The heat-shock, or HSF1-mediated proteotoxic stress, response in cancer: from proteomic stability to oncogenesis.Analysis of HSP90 Expression Is Valuable in the Differential Diagnosis of Ocular Surface Squamous Lesions.
P2860
Q26782145-98612B41-3753-456D-BFD4-FBBF4357AB05Q27023406-1656B8DE-8AF9-4BEE-954A-929D157DA654Q33632845-B463A339-C22A-4536-A258-48CFA68885BCQ33688445-8E9602D9-DFC5-4B0B-9F86-E73C7E3050B2Q34353920-F63F0B6E-6640-44C4-B99A-62C70C7EA0A4Q34752832-E5D6AF8A-BA67-400A-81E8-F634F957FBFCQ34999744-9779AF6B-FFCF-423F-8F63-DC1B4E35A3D4Q35689752-D6FD6986-A1D7-41C6-8724-C9AF8C82C82BQ35763206-5B12C17E-BC84-4B43-BA33-73FAE5824AD6Q36380237-B6DF9FDC-376E-47CE-ADB2-22273B506B38Q36546425-5B5F819D-EDAA-470A-BC6C-817D69E663F7Q36762341-4D427F04-3567-4C81-9428-853552387393Q36956034-4DEBC513-4054-42F4-9855-A8FCC1262001Q37060950-F34457DA-9010-4B39-BA19-ED70903B5B1FQ37168481-649D968C-6EF4-4713-BB85-C873B65C5C12Q37448116-1F0BD4C7-0151-4F56-82C4-CDA81A518763Q37536525-607821A8-DB89-40D7-B26A-BAEFDDBD92F3Q37689592-01FBDF45-BECF-4D68-942F-3A162B3F60FBQ37708836-0A030D3F-0EF9-4112-9177-02849A122605Q37726140-2C9377F8-2B1F-48D9-B05F-12BD2BC7D4A2Q37839615-D0D0E9E8-350C-41AD-8C2B-302A16F324B6Q38729418-6899536F-20A4-4350-B15E-570A3EC3ECF0Q38878493-ADE92FE6-19F8-4427-8620-D2988D8FC08EQ41854202-6348D93A-F314-41F9-9C5F-FB5460B52478Q41879186-0E638C1F-7677-45FE-9ABC-C008C2E4FCBAQ48096086-5C10A68D-A535-4903-8C73-9F9B33657A42Q50557388-AAFB24CC-5EE1-4B55-A766-B4B74332CD58Q54117138-131E8D81-0EA2-4A30-BEAC-6D631A097355
P2860
Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.
@ast
Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.
@en
type
label
Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.
@ast
Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.
@en
prefLabel
Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.
@ast
Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.
@en
P2093
P2860
P356
P1433
P1476
Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.
@en
P2093
Aarif Ahsan
Alnawaz Rehemtulla
Carter Van Waes
Christopher Gouveia
Christopher Whitehead
Dipankar Ray
Kristy Truong
Mukesh K Nyati
Shruti Jolly
Susan M Hiniker
P2860
P304
P356
10.1593/NEO.12986
P577
2012-08-01T00:00:00Z